Exagen Initiates Study to Predict Rheumatoid Arthritis Drug Response (RADR) in Patients with RA
04 août 2022 16h06 HE
|
Exagen Inc.
SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the launch of a prospective clinical study designed to...
Exagen Inc. Reports Second Quarter 2022 Results
04 août 2022 16h05 HE
|
Exagen Inc.
SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2022. ...
Exagen Inc. to Participate in the Canaccord Genuity 42nd Annual Growth Conference
25 juil. 2022 16h05 HE
|
Exagen Inc.
SAN DIEGO, July 25, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 42nd Annual...
Exagen to Announce Second Quarter 2022 Financial Results on August 4, 2022
21 juil. 2022 16h05 HE
|
Exagen Inc.
SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2022, after...
Exagen Releases Largest Comparative Utility Study in Lupus Diagnostics Confirming AVISE® Lupus Delivers Unparalleled Utility
05 juil. 2022 08h25 HE
|
Exagen Inc.
SAN DIEGO, July 05, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced new robust, real-world evidence confirming AVISE® testing...
Exagen Inc. Expands Coverage with MediNcrease
09 juin 2022 08h25 HE
|
Exagen Inc.
SAN DIEGO, June 09, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the addition of Exagen Inc. to MediNcrease Health Plans,...
Exagen Inc. to Participate in the William Blair 42nd Annual Growth Stock Conference
26 mai 2022 16h05 HE
|
Exagen Inc.
SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the William Blair 42nd Annual Growth...
Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE® Lupus
16 mai 2022 16h05 HE
|
Exagen Inc.
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® CTD and AVISE® Lupus are a contracted covered...
Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Test
11 mai 2022 16h06 HE
|
Exagen Inc.
SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Medicare Administrative Contractor (MAC) Noridian has...
Exagen Inc. Reports First Quarter 2022 Results
11 mai 2022 16h05 HE
|
Exagen Inc.
SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2022. ...